journal
https://read.qxmd.com/read/33939958/fractional-dose-compared-with-standard-dose-inactivated-poliovirus-vaccine-in-children-a-systematic-review-and-meta-analysis
#41
Thandiwe R Mashunye, Duduzile E Ndwandwe, Kopano R Dube, Muki Shey, Mary Shelton, Charles S Wiysonge
BACKGROUND: Since WHO recommended introduction of at least a single dose of inactivated poliovirus vaccine (IPV) in routine immunisation schedules, there have been global IPV shortages. Fractional-dose IPV (fIPV) administration is one of the strategies to ensure IPV availability. We reviewed studies comparing the effects of fractional with full-dose IPV vaccination to determine when seroconversion proportions with each strategy become similar in children aged 5 years and younger. METHOD: In this systematic review and meta-analysis, we searched 16 databases in July, 2019, for trials and observational studies, including ongoing studies that compare immunogenicity and adverse events of fractional-dose (0·1 mL) to full-dose (0·5 mL) IPV in healthy children aged 5 years or younger regardless of study design, number of doses, and route of administration...
April 30, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33930321/symptom-study-app-provides-real-world-data-on-covid-19-vaccines
#42
Ruth E Drury, Daniel O'Connor
No abstract text is available yet for this article.
April 27, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33930320/vaccine-side-effects-and-sars-cov-2-infection-after-vaccination-in-users-of-the-covid-symptom-study-app-in-the-uk-a-prospective-observational-study
#43
Cristina Menni, Kerstin Klaser, Anna May, Lorenzo Polidori, Joan Capdevila, Panayiotis Louca, Carole H Sudre, Long H Nguyen, David A Drew, Jordi Merino, Christina Hu, Somesh Selvachandran, Michela Antonelli, Benjamin Murray, Liane S Canas, Erika Molteni, Mark S Graham, Marc Modat, Amit D Joshi, Massimo Mangino, Alexander Hammers, Anna L Goodman, Andrew T Chan, Jonathan Wolf, Claire J Steves, Ana M Valdes, Sebastien Ourselin, Tim D Spector
BACKGROUND: The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. METHODS: In this prospective observational study, we examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine...
April 27, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33901417/correction-to-lancet-infect-dis-2021-published-online-april-19-https-doi-org-10-1016-s1473-3099-21-00227-9
#44
(no author information available yet)
No abstract text is available yet for this article.
April 23, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33894904/treponema-pallidum-detection-in-lesion-and-non-lesion-sites-in-men-who-have-sex-with-men-with-early-syphilis-a-prospective-cross-sectional-study
#45
Janet M Towns, David E Leslie, Ian Denham, Rebecca Wigan, Francesca Azzato, Deborah A Williamson, Darren Lee, Eric P F Chow, Christopher K Fairley, Stephen R Graves, Lei Zhang, Marcus Y Chen
BACKGROUND: Syphilis transmission is increasing, and precisely how Treponema pallidum is transmitted sexually from person to person is unclear. We aimed to determine the frequency of T pallidum shedding from potentially asymptomatic sites and the stage of infection at which shedding is most frequent in men who have sex with men (MSM), who have been disproportionately affected by syphilis. METHODS: We did a prospective, cross-sectional study in MSM recruited from Melbourne Sexual Health Centre (Melbourne, VIC, Australia)...
April 22, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33894903/a-conceptual-framework-to-accelerate-the-clinical-impact-of-evolving-research-into-long-covid
#46
Alexandra L Kondratiuk, Timesh D Pillay, Onn Min Kon, Ajit Lalvani
No abstract text is available yet for this article.
April 22, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33894132/monoclonal-antibodies-as-antibacterial-therapies-thinking-outside-of-the-box
#47
Marin H Kollef, Kevin D Betthauser
No abstract text is available yet for this article.
April 21, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33894131/efficacy-and-safety-of-suvratoxumab-for-prevention-of-staphylococcus-aureus-ventilator-associated-pneumonia-saatellite-a-multicentre-randomised-double-blind-placebo-controlled-parallel-group-phase-2-pilot-trial
#48
Bruno François, Hasan S Jafri, Jean Chastre, Miguel Sánchez-García, Philippe Eggimann, Pierre-François Dequin, Vincent Huberlant, Lucia Viña Soria, Thierry Boulain, Cédric Bretonnière, Jérôme Pugin, Josep Trenado, Ana Catalina Hernandez Padilla, Omar Ali, Kathryn Shoemaker, Pin Ren, Frank E Coenjaerts, Alexey Ruzin, Olivier Barraud, Leen Timbermont, Christine Lammens, Vadryn Pierre, Yuling Wu, Julie Vignaud, Susan Colbert, Terramika Bellamy, Mark T Esser, Filip Dubovsky, Marc J Bonten, Herman Goossens, Pierre-François Laterre
BACKGROUND: Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland...
April 21, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33894130/personalised-randomised-controlled-trial-designs-a-new-paradigm-to-define-optimal-treatments-for-carbapenem-resistant-infections
#49
REVIEW
A Sarah Walker, Ian R White, Rebecca M Turner, Li Yang Hsu, Tsin Wen Yeo, Nicholas J White, Mike Sharland, Guy E Thwaites
Antimicrobial resistance is impacting treatment decisions for, and patient outcomes from, bacterial infections worldwide, with particular threats from infections with carbapenem-resistant Enterobacteriaceae, Acinetobacter baumanii, or Pseudomonas aeruginosa. Numerous areas of clinical uncertainty surround the treatment of these highly resistant infections, yet substantial obstacles exist to the design and conduct of treatment trials for carbapenem-resistant bacterial infections. These include the lack of a widely acceptable optimised standard of care and control regimens, varying antimicrobial susceptibilities and clinical contraindications making specific intervention regimens infeasible, and diagnostic and recruitment challenges...
April 21, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33891908/quantifying-the-rates-of-late-reactivation-tuberculosis-a-systematic-review
#50
REVIEW
Katie D Dale, Malancha Karmakar, Kathryn J Snow, Dick Menzies, James M Trauer, Justin T Denholm
The risk of tuberculosis is greatest soon after infection, but Mycobacterium tuberculosis can remain in the body latently, and individuals can develop disease in the future, sometimes years later. However, there is uncertainty about how often reactivation of latent tuberculosis infection (LTBI) occurs. We searched eight databases (inception to June 25, 2019) to identify studies that quantified tuberculosis reactivation rates occurring more than 2 years after infection (late reactivation), with a focus on identifying untreated study cohorts with defined timing of LTBI acquisition (PROSPERO registered: CRD42017070594)...
April 20, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33887210/recombinant-protein-vaccines-against-sars-cov-2
#51
Sarah C Gilbert, Teresa Lambe
No abstract text is available yet for this article.
April 19, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33887209/safety-and-immunogenicity-of-sars-cov-2-recombinant-protein-vaccine-formulations-in-healthy-adults-interim-results-of-a-randomised-placebo-controlled-phase-1-2-dose-ranging-study
#52
Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, Ian Frank, Owen Haney, Helene Janosczyk, Michael C Keefer, Marguerite Koutsoukos, Murray A Kimmel, Roger Masotti, Stephen J Savarino, Lode Schuerman, Howard Schwartz, Lawrence D Sher, Jon Smith, Fernanda Tavares-Da-Silva, Sanjay Gurunathan, Carlos A DiazGranados, Guy de Bruyn
BACKGROUND: CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2. We present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations. METHODS: This phase 1-2, randomised, double-blind study is being done in healthy, SARS-CoV-2-seronegative adults in ten clinical research centres in the USA. Participants were stratified by age (18-49 years and ≥50 years) and randomly assigned using an interactive response technology system with block randomisation (blocks of varying size) to receive one dose (on day 1) or two doses (on days 1 and 22) of placebo or candidate vaccine, containing low-dose (effective dose 1·3 μg) or high-dose (2·6 μg) antigen with adjuvant AF03 (Sanofi Pasteur) or AS03 (GlaxoSmithKline) or unadjuvanted high-dose antigen (18-49 years only)...
April 19, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33887208/safety-and-immunogenicity-of-an-mf59-adjuvanted-spike-glycoprotein-clamp-vaccine-for-sars-cov-2-a-randomised-double-blind-placebo-controlled-phase-1-trial
#53
Keith J Chappell, Francesca L Mordant, Zheyi Li, Danushka K Wijesundara, Paula Ellenberg, Julia A Lackenby, Stacey T M Cheung, Naphak Modhiran, Michael S Avumegah, Christina L Henderson, Kym Hoger, Paul Griffin, Jillian Bennet, Luca Hensen, Wuji Zhang, Thi H O Nguyen, Sara Marrero-Hernandez, Kevin J Selva, Amy W Chung, Mai H Tran, Peter Tapley, James Barnes, Patrick C Reading, Suellen Nicholson, Stavroula Corby, Thomas Holgate, Bruce D Wines, P Mark Hogarth, Katherine Kedzierska, Damian F J Purcell, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R Young, Trent P Munro
BACKGROUND: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential paediatric use. We aimed to assess the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp (spike glycoprotein-clamp [sclamp])...
April 19, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33887207/covid-19-herd-immunity-by-immunisation-are-children-in-the-herd
#54
Stephen Obaro
No abstract text is available yet for this article.
April 19, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33872594/cryptococcal-meningoencephalitis-time-for-action
#55
REVIEW
Katharine Elizabeth Stott, Angela Loyse, Joe N Jarvis, Melanie Alufandika, Thomas Stephen Harrison, Henry C Mwandumba, Jeremy N Day, David G Lalloo, Tihana Bicanic, John R Perfect, William Hope
Cryptococcal meningoencephalitis was first described over a century ago. This fungal infection is preventable and treatable yet continues to be associated with excessive morbidity and mortality. The largest burden of disease resides in people living with HIV in low-income and middle-income countries. In this group, mortality with the best antifungal induction regimen (7 days of amphotericin B deoxycholate [1·0 mg/kg per day] and flucytosine [100·0 mg/kg per day]) in a clinical trial setting was 24% at 10 weeks...
April 16, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33872593/correction-to-lancet-infect-dis-2021-published-online-march-25-https-doi-org-10-1016-s1473-3099-21-00132-8
#56
(no author information available yet)
No abstract text is available yet for this article.
April 16, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33865461/laboratory-informatics-capacity-for-effective-antimicrobial-resistance-surveillance-in-resource-limited-settings
#57
REVIEW
Paul Turner, Priscilla Rupali, Japheth A Opintan, Walter Jaoko, Nicholas A Feasey, Sharon J Peacock, Elizabeth A Ashley
Antimicrobial resistance (AMR) is a major threat to human health globally. Surveillance is a key activity to determine AMR burden, impacts, and trends and to monitor effects of interventions. Surveillance systems require efficient capture and onward sharing of high-quality laboratory data. Substantial investment is being made to improve laboratory capacity, particularly in low-income and middle-income countries (LMICs) with high disease burdens. However, building capacity for effective laboratory data management remains an under-resourced area, which, unless addressed, will limit progress towards comprehensive AMR surveillance in LMICs...
April 15, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33864804/lowering-sars-cov-2-viral-load-might-affect-transmission-but-not-disease-severity-in-secondary-cases-authors-reply
#58
LETTER
Matthew A Spinelli, George Rutherford, Monica Gandhi
No abstract text is available yet for this article.
April 14, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33864803/lowering-sars-cov-2-viral-load-might-affect-transmission-but-not-disease-severity-in-secondary-cases
#59
LETTER
Mattia Trunfio, Andrea Calcagno, Stefano Bonora, Giovanni Di Perri
No abstract text is available yet for this article.
April 14, 2021: Lancet Infectious Diseases
https://read.qxmd.com/read/33864802/has-artemisinin-resistance-emerged-in-africa
#60
Philip J Rosenthal
No abstract text is available yet for this article.
April 14, 2021: Lancet Infectious Diseases
journal
journal
20187
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"